Cue Biopharma (NASDAQ:CUE) Raised to Strong-Buy at Wall Street Zen

Key Points

• Analyst split: Wall Street Zen upgraded Cue Biopharma to a "strong-buy" from "buy", while Weiss Ratings reaffirmed a "sell" and the consensus rating remains Sell, indicating mixed analyst views.
• Shares jumped about 6.4% to open at $17.70, with a market capitalization of roughly $1.72 billion and a 52‑week range of $4.97 to $30.90.
• Cue is still largely unprofitable despite reporting $0.30 EPS and $21.94 million in quarterly revenue, showing a negative net margin of 96.85% and negative ROE of 165.19%, while institutional investors own about 35% of the stock.

Cue Biopharma (NASDAQ:CUE - Get Free Report) was upgraded by Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Saturday.

Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Cue Biopharma in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Cue Biopharma currently has a consensus rating of "Sell".

Cue Biopharma Stock Up 6.4%

Shares of NASDAQ:CUE opened at $17.70 on Friday. Cue Biopharma has a 52 week low of $4.97 and a 52 week high of $30.90. The stock has a market capitalization of $1.72 billion, a P/E ratio of -55.30 and a beta of 1.57. The firm has a fifty day simple moving average of $10.25 and a two-hundred day simple moving average of $13.57.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last issued its quarterly earnings data on Monday, March 16th. The company reported $0.30 EPS for the quarter. Cue Biopharma had a negative net margin of 96.85% and a negative return on equity of 165.19%. The business had revenue of $21.94 million during the quarter.

Hedge Funds Weigh In On Cue Biopharma

A number of large investors have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. lifted its holdings in Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company's stock valued at $57,000 after buying an additional 73,000 shares in the last quarter. Squarepoint Ops LLC bought a new stake in Cue Biopharma during the 3rd quarter valued at about $62,000. Boothbay Fund Management LLC bought a new stake in Cue Biopharma during the 3rd quarter valued at about $439,000. GC Wealth Management RIA LLC lifted its holdings in Cue Biopharma by 35.0% during the 4th quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company's stock valued at $1,415,000 after buying an additional 1,200,000 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc lifted its holdings in Cue Biopharma by 1,231.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company's stock valued at $135,000 after buying an additional 407,568 shares in the last quarter. 35.04% of the stock is owned by hedge funds and other institutional investors.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company's proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.